Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer

NCT04192682 is registered in ClinicalTrials.gov with Changzhou Cancer Hospital of Soochow University as lead sponsor.

NCT NCT04192682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04192682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer
Lead sponsor
Changzhou Cancer Hospital of Soochow University
Phase
Phase 2/3
Overall status
Unknown status
Start date
May 8, 2019
Completion date
July 1, 2021
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer